Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2021

Open Access 01-12-2021 | Erythropoietin | Case report

Megaloblastic anemia-related iron overload and erythroid regulators: a case report

Authors: Nicolas Vallet, Jean-Baptiste Delaye, Martine Ropert, Amélie Foucault, Noémie Ravalet, Sophie Deriaz, Thomas Chalopin, Hélène Blasco, François Maillot, Olivier Hérault, Emmanuel Gyan

Published in: Journal of Medical Case Reports | Issue 1/2021

Login to get access

Abstract

Background

In ineffective erythropoiesis, hepcidin synthesis is suppressed by erythroid regulators, namely erythroferrone and growth differentiation factor-15. For the first time, the hypothesis that iron overload in megaloblastic anemia may be related to ineffective erythropoiesis is explored by describing the kinetics of hepcidin, erythroferrone, and growth differentiation factor-15 levels in a patient diagnosed with megaloblastic anemia associated with iron overload.

Case presentation

An 81-year-old Caucasian male was admitted for fatigue. He had type-2 diabetes previously treated with metformin, ischemic cardiac insufficiency, and stage-3 chronic kidney disease. Vitiligo was observed on both hands. Biological tests revealed normocytic non-regenerative anemia associated with hemolysis, thrombocytopenia, and elevated sideremia, ferritin, and transferrin saturation levels. Megaloblastic anemia was confirmed with undetectable blood vitamin B12 and typical cytological findings like hyper-segmented neutrophils in blood and megaloblasts in bone marrow. The patient received vitamin B12 supplementation. At 3 months, biological parameters reached normal values. Hepcidin kinetics from diagnosis to 3 months inversely correlated with those of erythroferrone and growth differentiation factor-15.

Conclusions

This case suggests that iron-overload mechanisms of dyserythropoietic anemias may apply to megaloblastic anemias.
Literature
1.
go back to reference Green R. Vitamin B12 deficiency from the perspective of a practicing hematologist. Blood. 2017;129(19):2603–11.CrossRef Green R. Vitamin B12 deficiency from the perspective of a practicing hematologist. Blood. 2017;129(19):2603–11.CrossRef
2.
go back to reference Ho C-H, You J-Y, Chau W-K, et al. Diagnostic value of serum transferrin receptor and glycosylated hemoglobin on hemolytic anemia. Ann Hematol. 2003;82(4):228–30.CrossRef Ho C-H, You J-Y, Chau W-K, et al. Diagnostic value of serum transferrin receptor and glycosylated hemoglobin on hemolytic anemia. Ann Hematol. 2003;82(4):228–30.CrossRef
3.
go back to reference Ganz T, Jung G, Naeim A, et al. Immunoassay for human serum erythroferrone. Blood. 2017;130(10):1243–6.CrossRef Ganz T, Jung G, Naeim A, et al. Immunoassay for human serum erythroferrone. Blood. 2017;130(10):1243–6.CrossRef
4.
go back to reference Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13(9):1096–101.CrossRef Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13(9):1096–101.CrossRef
5.
go back to reference Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica. 2020;105(2):260–72.CrossRef Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica. 2020;105(2):260–72.CrossRef
6.
go back to reference Hanudel MR, Rappaport M, Chua K, et al. Levels of the erythropoietin-responsive hormone erythroferrone in mice and humans with chronic kidney disease. Haematologica. 2018;103(4):e141–2.CrossRef Hanudel MR, Rappaport M, Chua K, et al. Levels of the erythropoietin-responsive hormone erythroferrone in mice and humans with chronic kidney disease. Haematologica. 2018;103(4):e141–2.CrossRef
7.
go back to reference Coll AP, Chen M, Taskar P, et al. GDF15 mediates the effects of metformin on body weight and energy balance. Nature. 2020;578(7795):444–8.CrossRef Coll AP, Chen M, Taskar P, et al. GDF15 mediates the effects of metformin on body weight and energy balance. Nature. 2020;578(7795):444–8.CrossRef
8.
go back to reference Ashby DR, Gale DP, Busbridge M, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009;75(9):976–81.CrossRef Ashby DR, Gale DP, Busbridge M, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009;75(9):976–81.CrossRef
9.
go back to reference van Vuren AJ, Eisenga MF, van Straaten S, et al. Interplay of erythropoietin, fibroblast growth factor 23, and erythroferrone in patients with hereditary hemolytic anemia. Blood Adv. 2020;4(8):1678–82.CrossRef van Vuren AJ, Eisenga MF, van Straaten S, et al. Interplay of erythropoietin, fibroblast growth factor 23, and erythroferrone in patients with hereditary hemolytic anemia. Blood Adv. 2020;4(8):1678–82.CrossRef
10.
go back to reference Theurl I, Finkenstedt A, Schroll A, et al. Growth differentiation factor 15 in anaemia of chronic disease, iron deficiency anaemia and mixed type anaemia. Br J Haematol. 2010;148(3):449–55.CrossRef Theurl I, Finkenstedt A, Schroll A, et al. Growth differentiation factor 15 in anaemia of chronic disease, iron deficiency anaemia and mixed type anaemia. Br J Haematol. 2010;148(3):449–55.CrossRef
11.
go back to reference Casanovas G, Swinkels DW, Altamura S, et al. Growth differentiation factor 15 in patients with congenital dyserythropoietic anaemia (CDA) type II. J Mol Med. 2011;89(8):811–6.CrossRef Casanovas G, Swinkels DW, Altamura S, et al. Growth differentiation factor 15 in patients with congenital dyserythropoietic anaemia (CDA) type II. J Mol Med. 2011;89(8):811–6.CrossRef
12.
go back to reference Hao S, Xiang J, Wu D-C, et al. Gdf15 regulates murine stress erythroid progenitor proliferation and the development of the stress erythropoiesis niche. Blood Adv. 2019;3(14):2205–17.CrossRef Hao S, Xiang J, Wu D-C, et al. Gdf15 regulates murine stress erythroid progenitor proliferation and the development of the stress erythropoiesis niche. Blood Adv. 2019;3(14):2205–17.CrossRef
13.
go back to reference Mangaonkar AA, Thawer F, Son J, et al. Regulation of iron homeostasis through the erythroferrone-hepcidin axis in sickle cell disease. Br J Haematol. 2020;189(6):1204–9.CrossRef Mangaonkar AA, Thawer F, Son J, et al. Regulation of iron homeostasis through the erythroferrone-hepcidin axis in sickle cell disease. Br J Haematol. 2020;189(6):1204–9.CrossRef
14.
go back to reference Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678–84.CrossRef Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678–84.CrossRef
Metadata
Title
Megaloblastic anemia-related iron overload and erythroid regulators: a case report
Authors
Nicolas Vallet
Jean-Baptiste Delaye
Martine Ropert
Amélie Foucault
Noémie Ravalet
Sophie Deriaz
Thomas Chalopin
Hélène Blasco
François Maillot
Olivier Hérault
Emmanuel Gyan
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2021
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-021-03065-0

Other articles of this Issue 1/2021

Journal of Medical Case Reports 1/2021 Go to the issue